8th BenBedPhar Scientific Meeting | October 10-11, 2024 |Lisbon, Portugal
BenBedPharis the acronym of the COST (European Cooperation in Science and Technology)Action “Bench to bedside transition for pharmacological regulation of NRF2 innon-communicable diseases” of which our PostDoc Christina Morgenstern is one ofthe working group leaders. From the 10th until the 11thof October the 8th BenBedPhar management and scientific meeting washeld at NOVA Medical School in Lisbon, Portugal and gathered experts discussingadvancements in the understanding of NRF2 pathway’s role in health and disease.The conference was themed “Thirty Years since the Discovery of NRF2” andincluded topics about the role of the transcription factor NRF2 as a masterregulator of cytoprotective responses in a variety of diseases as well as novelideas on therapeutic approaches and drug discovery.
Christinapresented the progress report of the working group 3 – Translational Medicine –in the preceding management committee meeting as well as chaired the scientificsession “New tools and drug discovery targeting NRF2”. The former was wellreceived by the management committee as the deliverables of working group 3 areadvancing and will be published as review articles soon.
Apart fromstrategic operations and engaging scientific discussions around NRF2, the BenBedPhargroup explored the historic NOVA Medical School campus and Lisbon city centerthrough an organised tour.
Moreinformation on the COST-Action:
https://www.cost.eu/actions/CA20121/
Meetingprogramme:
https://benbedphar.org/8th-benbedphar-scientific-meeting/
